Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With $5B under management, a diversified fund and over 190 exits to date, Canaan has invested in some of the world's leading technology and healthcare companies over the past 30 years. Canaan’s focus areas include fintech, enterprise/cloud, marketplaces, frontier tech, biopharma, digital health, and medtech.

Canaan Partners

Warburg Pincus is a private equity firm focused on growth investing.

Warburg Pincus

Founded in 1988, St. Paul Venture Capital is one of the largest  early-stage venture capital funds in the United States with $3.0 billion in  committed capital and offices in Minneapolis, Boston and Silicon Valley.  With  The St. Paul Companies as a single limited partner, the firm invests primarily  in the areas of Communications, Software and Services and Healthcare.  For  more information, visit the firm's website at http://www.spvc.com

St. Paul Venture Capital

Provides venture capital and expertise to early-stage, technology-based businesses specializing in communications.

RWI Group

Since its inception in 1998, Windamere Venture Partners has supported more than a dozen pharmaceutical, biotechnology, medical device, and other healthcare companies from the very early stages. Their unique approach combines a specialized investment focus with active management and long-term commitment to ensure the highest rates-of-return for both entrepreneurs and investors.

Windamere Venture Partners

Fog City Capital is a private equity firm focused exclusively on investments in outsourced business services and technologies within those sectors.

Fog City Capital

Federated Kaufmann Fund is an investment management firm that specializes in the fields of mutual funds, managed accounts institutional, and separate accounts. IT offers equity, international, fixed income, alternative, and money market strategies.

Federated Kaufmann Fund

Dexcom

Membership-based, non-insurance healthcare companies helping maintain a steady state of well being.

Preventive Healthcare

Beta Bionics, a medical technology company, developed the iLet Bionic Pancreas for people with type 1 diabetes. It is an automated system that can deliver insulin in one or two hormone modes, automatically calculating and administering all insulin doses needed. The FDA-approved iLet Bionic Pancreas eliminates traditional setup, carbohydrate counting, correction, and bolus calculation.&nbsp;The system is compatible with two continuous glucose monitoring (CGM) systems: the Dexcom CGM and the Senseonics Eversense CGM. It is a pocket-sized, wearable medical device that uses ML algorithms to control blood sugar levels in people with diabetes. It can be configured as an insulin-only bionic pancreas, a glucagon-only bionic pancreas, or a dual-hormone bionic pancreas.Key customers and partnershipsThe company has collaborated with pharmaceutical companies to improve its lead technology: <a href="https://www.betabionics.com/zealand-and-beta-bionics-to-collaborate-on-the-development-of-a-first-in-class-dual-hormonal-bionic-pancreas-system-for-treatment-of-people-with-type-1-diabetes/">Zealand Pharma</a> (June 2016) to develop a new dual-hormonal artificial pancreas system for the treatment of diabetes and <a href="https://www.betabionics.com/beta-bionics-and-convatec-announce-partnership-to-bring-unomedical-infusion-set-portfolio-to-the-ilet-bionic-pancreas-system/">ConvaTec</a> (July 2019) to manufacture infusion sets for use with Beta Bionics' iLet Bionic Pancreas System, which autonomously controls blood sugar levels in people with diabetes.&nbsp;Funding and financialsIn August 2023, the company raised USD 100 million in <a href="https://sp-edge.com/updates/21628">Series D funding</a> co-led by Sands Capital and Omega Funds to expand access to the iLet Bionic Pancreas across the US and further develop and test the bi-hormonal bionic pancreas.

More important now than ever, telehealth will long outlast the pandemic that drove its growth.

Telehealth

<div>
 
 Current Health is a B2B remote patient monitoring platform, offering at-home health care services. The company provides patients with a pre-configured home kit that includes its own US Food and Drug Administration (FDA) cleared biosensor, OmniVitals, to record patient vitals. The company claims the wearable device can monitor vitals with the same accuracy as an ICU monitor. The information is available for review by doctors via the platform and if any abnormalities are detected, Current Health&rsquo;s 24/7 triage team will determine the appropriate steps to be taken which could include a telehealth visit with the patient&rsquo;s doctor. 
 
 
 In addition, Current Health offers hospital-at-home programs to manage high-risk patients by incorporating remote monitoring, AI-based smart alerts, and integrated telemedicine to avoid hospitalization. Once the patient recovers, the at-home kit is collected from the patient, recycled, and delivered back to the hospital. The company also launched a range of in-home services in August 2021 together with Workpath for blood draws and ScriptDrop for medication delivery. Current Health plans to collaborate with other startups to expand its offering to include services such as transportation and in-home infusion therapy.&nbsp;
 
 
 Founded in 2015, Current Health specializes in pre and post-surgery, chronic conditions, oncology, and Covid-19. Current Health&rsquo;s key customers include leading health systems and pharmaceutical companies, such as Mayo Clinic, Mount Sinai, National Health Service, Baptist Health, AstraZeneca, Geisinger, Massachusetts General Hospital, and Amgen. The platform has partnered with medical device manufacturers Dexcom, VivaLNK, MIR, and Omran to deploy in specific clinical areas. 
 
 
 The company concluded an oversubscribed Series B funding round in April 2021, which will be used to expand its geographic footprint across the globe. In October 2021, global consumer electronics retailer Best Buy announced its plans to acquire Current Health. It plans to combine Current Health's portfolio of services with its existing products and services, offering a holistic approach to senior care delivery. Following the acquisition, Boston and UK-based Current Health will benefit from access to Best Buy&rsquo;s sizable physical footprint, tech support, and logistics.
 
</div>

Leveraging personal data for custom-fit diagnosis and treatment

Precision Medicine

Phenomix Sciences is a precision medicine biotechnology company focused on addressing obesity through data-driven approaches. Phenomix leverages phenotyping—a method that combines genetic, environmental, and behavioral factors to tailor obesity treatments.&nbsp;The company’s flagship product, the MyPhenome test, identifies specific obesity phenotypes such as Hungry Gut, Hungry Brain, Emotional Hunger, and Slow Burn, to predict patient responses to various treatments, including diet modifications, GLP-1 medications, and surgical interventions​.<h3>Key customers and partnerships</h3>In February 2023, Phenomix partnered with Kailos Genetics to process genetic analyses for its obesity phenotyping tests​. This partnership enabled the integration of cutting-edge gene sequencing with Phenomix's predictive analytics, providing healthcare providers with actionable insights to personalize obesity treatments.

Redefining hospital care with the comfort of home

Hospital-at-Home

Current Health is a healthcare technology company that provides a care-at-home platform designed to transform healthcare delivery. The company's solution combines continuous vitals monitoring with 24/7 nursing support to enable hospitals to extend acute care services into patients' homes. This approach aims to improve patient outcomes while reducing the burden on healthcare facilities. Current Health's platform offers configurable monitoring and clinical pathways to support post-discharge care and improve surgical throughput. The system integrates with electronic health records (EHR) and includes communication tools to facilitate medication management and care coordination for rising-risk populations.
The company's technology has demonstrated significant benefits in various healthcare settings. For instance, UMass Memorial Health reported saving more than 6,000 bed days in their first year of using the platform. In another case, Baptist Health achieved a 0% 90-day readmission rate among high-risk heart failure patients. OSF healthcare experienced a nearly 30% reduction in costs for complex patients using Current Health's solution. The platform also supports clinical trials by enabling more flexible study designs with less reliance on site visits. In one study, participants showed 70% adherence to the Current Health wearable device and 80% adherence to surveys. Additionally, the technology has shown promise in early detection of adverse events in treatments such as CAR-T therapy. A study at Mount Sinai found that the platform could detect early signs of cytokine release syndrome (CRS) 206 minutes earlier than standard care practices.

Phenomix Sciences is a biotechnology company that specializes in biotech, life science, metabolomics, and genomics. It provides healthcare solutions that will enable personalized management of chronic diseases with better efficacy, fewer side effects, and lower costs. The company was founded in 2017 and headquartered in New York, United States.

Current Health help healthcare reduces risk & cost by monitoring, managing, and engaging patients at home.

Beta Bionics is a biotechnology company that develops an integrated bionic pancreas system called the iLet. The iLet Bionic Pancreas System was granted breakthrough designation in all configurations (insulin-only, glucagon-only, and bihormonal), including use with Zealand Pharma’s dasiglucagon, a glucagon analogue with a stability profile in a ready-to-use aqueous solution. It also offers a bionic pancreas device for glucose metabolism to the diabetes community.

DexCom is a developer of glucose sensing technologies and focuses on these technologies. Founded in 1999, DexCom's roots stem from the pioneering 1967 research on implanted glucose sensors at the University of Wisconsin. DexCom started with a focus on creating an implantable Sensor that the body would not reject and that would perform for a long period of time.

<div> DexCom, Inc. is a leader in continuous glucose sensing technologies, and focuses 100% on these technologies. Founded in 1999, DexCom&acirc;&euro;&trade;s roots stem from the pioneering 1967 research on implanted glucose sensors at the University of Wisconsin. DexCom started with a focus on creating an implantable Sensor that the body would not reject and that would perform for a long period of time. </div>

$100 Invested In DexCom 15 Years Ago Would Be Worth This Much Today

From counting steps to saving lives and beyond

Wearable Tech

Wearable devices in form factors, such as wristwear and rings, designed to monitor and track various aspects of a person's physical activity, health, and wellness

Wearable entertainment devices designed primarily for entertainment and leisure purposes. These come in the form of hearables, wearable cameras, personalized smart devices, etc.

Apparel that incorporate electronic components, sensors, and connectivity features to provide functionalities beyond traditional clothing and accessories

Specialized wearable devices designed for use in industrial and work settings. These include safety wearables that come in the form of head-mounted devices, smart gloves, exoskeletons, etc.

Wearable devices, which are designed to monitor, collect, and transmit various health-related data, and wearable assistive devices. These come in the form of cardiac monitoring devices, glucose monitors, wearable pulse oximeters, hearing impairment aids, visual aids, etc.

Dexcom

Featured Industries

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless